Navigation Links
Risk Of Death Increases With Sudden Withdrawal Of Medications

Journal of the American Heart Association reported that patients who had heart attack, and stopped taking antiplatelet drugs within 30 days of having //a drug-coated with stent have 7 times more risk of death than others.

"An alarming one in seven patients in our study stopped taking their antiplatelet medication within the first 30 days of receiving a drug-eluting stent (DES), even though they were prescribed the drugs at the time of hospital discharge and recommendations are to continue them for a minimum of three to six months after the procedure," said John A. Spertus, M.D., M.P.H., lead author of the study and director of cardiovascular education and outcomes research at the Mid America Heart Institute in Kansas City, Mo.

Researchers looked at the real-world use of DES in heart attack patients and a class of drugs called thienopyridines that work along with aspirin to help keep platelets in the blood from clumping and leading to the formation of blood clots. Thienopyridines include the drugs clopidogrel and ticlopidine. Blood clots can obstruct a coronary artery, causing a heart attack.

Several studies have confirmed the benefits of DES in preventing restenosis (reclosing of the artery that had been treated). However, with stents there is the potential problem of stent thrombosis (blood clots forming inside the stent), which can be associated with devastating consequences. Antiplatelet agents, including thienopyridines, reduce the likelihood of stent thrombosis. According to Spertus, no previous studies have defined the frequency and consequences of prematurely discontinuing thienopyridine therapy.

The risk of stent thrombosis with bare-metal stents (stents not coated with a drug) decreases rapidly after two to four weeks, and patients typically need thienopyridines for only about one month. In comparison, with drug-eluting stents the risk of stent thrombosis lasts for a longer period of time and patients with DES requir
'"/>




Page: 1 2 3

Related medicine news :

1. White Cells Count Can Predict Heart Attack Death Risk
2. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
3. AIDS toll set to exceed Black Death
4. Fish Oil Fights Arrhythmias, Sudden Death
5. Painkiller Linked to Deaths
6. Death due to premature heartbeat after exercise
7. Preventing Childhood Deaths
8. Death Risk Higher in Obese Women with Colon Cancer
9. Death Among the Homeless
10. Diabetes on the Increase but Death Rate Falling
11. Drug Users and Risk of Death
Post Your Comments:
(Date:10/8/2008)...n & Laser Center is well established as a tech...w York City. The facility is living up to its repu... skin resurfacing treatments to receive FDA approv..., New York, NY (PRWEB) Oct...atment industry is in the midst of an unprecedente...
(Date:10/7/2008)...elated Questions for Tonight,s,Presidential Debate...D, the leading source of,health information, today...ndidates, proposed health care policies, located a...candidates, stance on health insurance, medical an...c health issues., The in-depth coverage is just o...
(Date:10/7/2008)...Newswire-USNewswire/ -- IPRO, one of the,nation,s ...ations, has,created a Limited Liability Company (L...t oversight and consulting contracts with managed ...l (http://www.logiqual.com ), is now,officially i...w.newscom.com/cgi-bin/prnh/20081007/DC37283LOGO-a ...
(Date:10/7/2008)...-USNewswire/ -- As the presidential,candidates com...ate, Jean,Berg, a nursing assistant and member of ...waiting to ask John McCain why he wants to tax hea...o afford coverage., Berg has been a nursing assis...are., "It,s the single biggest economic factor in...
Breaking Medicine News(10 mins):Health News:Upscale New York City Skin Care Center Juva Offering FDA Approved Fraxel re:fine System 2Health News:WebMD Highlights Presidential Candidates' Views on Health Care 2Health News:IPRO Spins Off Managed Care Review Affiliate 2Health News:SEIU Member Will Be in Town Hall Audience, Ready to Ask John McCain Why He Won't Provide Affordable Healthcare for All 2
...eading player in the Indian drug industry, has rec...Authority (FDA) for three// of its abbreviated new...d will be launching this product in the US through...potex, the Chennai-based company said in a release...
...eople suffering from osteoporosis are not told abo...cording to the research by the University of Weste...alians being affected by osteoporosis, the problem...ly. Dr Charles Inderjeeth from the School of Popu...
...rimination against HIV/AIDS victims will be tabled...or approval.// In the light of the XVI Internatio...i Ramadoss said, "it took a little time, because w...d elaborate discussions with the stakeholders. Hop...
...ed yesterday that a Walkers crisps advertising cam...ntent.// According to the industry watchdog a pro...salt in its crisps to "7% of your guideline daily ...act that the reduction did not apply to all Walker...
Other Medicine News:Health News:Negligence in Osteoporosis treatment 2Health News:Legislation to Prevent Discrimination against HIV/AIDS Victims 2
(Date:10/7/2008)... FORT COLLINS, Colo., Oct. 7 /- A...examining embryonic stem cell self-renewal,report...lastim (recombinant,human serum albumin) was an ef...cell culture., The article entitled, "The ground ...sed that researchers used Cellastim as a recombina...
(Date:10/7/2008)... CAMBRIDGE, Mass., Oct. 7 /- Tali... data on several of the Company,s pipeline,candida...ement Workshop in,Basel, Switzerland. The data hig...l models of complement-mediated diseases., "These...vitro studies,presented at the conference, reveal ...
(Date:10/7/2008)... Several abstracts highlighting CIMZIA,s long-...n,s disease patients presented at American College.../- Data from two studies,pr...f Gastroenterology,(ACG) Annual Meeting demonstrat...EGylated anti-TNF alpha (Tumor Necrosis Factor alp...
(Date:10/7/2008)... SAN DIEGO, Oct. 7 /- A...today that a poster entitled "RDEA119, a Potent,an...in Dextran Sulfate,Sodium (DSS) -- induced Chronic...ollege of Gastroenterology (ACG) 2008 Annual Meeti... data from a preclinical study of,RDEA119, the Com...
Breaking Medicine Technology:In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4The story of Max Perutz a pioneering biologist with a remarkable passion for life 2832 1Nominations for Outstanding Cancer Survivor Award Being Accepted by Karmanos Cancer Institute Through April 27 16388 1Nominations for Outstanding Cancer Survivor Award Being Accepted by Karmanos Cancer Institute Through April 27 16388 2Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 1Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 2Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 3ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 1ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 2ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 3ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 4ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 5ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 6ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 7
...ontinuous low-flow nebulizer performance. Patented...allows for optimal medication and Heliox delivery ...vere asthma, COPD and pneumonia in both routine an... mouth and T-piece to deliver high-output, low-flo...
... diverse medical products for more than 58 years. ...anding reputation for innovation, quality and cust...ecognized brands include the Labtron® line of ... products, Bristoline® microscopes, HealthTeam...
...contains everything the health care professional n...ickly and efficiently: 7 nebulizers, T-piece and m...yringe and needle., ,Shipped 5 kits per case., ,...ed Use: AsthmaKit is a procedural kit providing th...
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only
Medicine Products: